Thank hello the to call and on you, today. everyone Kathy
programs the releases of few we're remaining primarily the update provide next also STAR-T the on discuss to highlight progress some company that data year. trial, happened major clinical and For minutes, course, and the this an already going
next slide, So please.
we clinical update you very all for I'm discuss now clinical to call to the that So the increased report our it's headline resources, on solid on Canada, our last focusing all and happy on visibility earnings and forward. is expanding have off. with made as The moving strategy STAR-T progress have that trial we today's the paying that we're resource
XX fully than has patients will we reiterate spring summer. hit more trial the point will next patients and of crossed timelines halfway stated of enrolled. this fast the enrolling is with that milestone this previously now STAR-T the and enroll can We the XX now
registry, activities The enrolled have upon the rates STAR-D plan with we this we of the enrollment of remain before and the the patients also fact, will very study STAR-T first encouraging that this completion readouts STAR-T. of initial remains have year. to half resume in on pause Also enough data
publications study clinical year registry, randomized our process, enrollment. our specifically stream and focus for positive will surgery. continue with a critical conference care, COSMOS we critical and in CytoSorb journals And care, on in international and and to this trials will our data accelerating peer-reviewed flow accelerate constant of the in international and also large We're in which all finally, liver therapeutic XXXX areas including cardiac presentations kidney
Next slide, please.
spend slides STAR-T. the about let's talking of next Now couple
we forward. As I visibility mentioned, way now the of good have
a without a reminder, the received we of the planned XX patients first the after study as at Just end last finished we from green continue as and enrolled modification. December, in were DSMB recommended safety their that review who light first any to year
came Canada Since came of multiple study and in accelerating sites in the enrollment majority the fast, on the accelerating that experienced have already and contributed. are and trial we participant but it's quickly has also. enrollment contributed patients now actively on time,
upon are the we an very thankful in be also that regulatory a for passed driving And to as colleagues. note, expert Now working will point, welcome, that our of us, critical the Irina filing with trial. FDA to joining we're closely such side the I be halfway the would like regulatory experienced completion
reviewed already And shown you on completed milestones one the before, were the trial the you that three bottom outlining slide, see already. that as been with of has of table the first the we've the
closed enrolled. once should XXX we next which which The spring the out XX of one, in anticipated patients review, patients, for is DSMB study which And full what milestone, hit represents then place looking we happening summer. the this analysis of final will we the the second be follow take enrollment this the with
please. slide, Next
more is a completion. want trial the in the I few give bit you months little to as coming to next insight
the for a So to bit let's talk STAR-T future in what about expect little near trial. the
so-called event with First based we a database that forgoing be of the you log process time be the an of that analysis enrolled performing estimate and the have the so. fully to interim to analysis we I'd remind soft a the previously by an the interim Therefore, the to cleaning the all, opportunity plan enrollment, analysis trial comes all interim that alpha. requires full we full adjudication, data process scheduled by completed. will like would final The alpha price, preserve for fast on now spend analysis with do statistical and also
this related investigative concerns. U.S. that the emphasize motivated it's to direct is fast any of to related or directly enrollment will positive all I and the in other a of at is sites not trial, and which highly result Canada, the known development safety
is So patients, press last what which we enrollment the year we XX will next similar trigger did a should in be looking of for release. as late
likely XX will patients second be we from to DSMB approximately executing safety that press – the review interval review, DSMB from the between one similar the the weeks. And and that following review eight enrolling and the on anticipate point the the
Next slide.
next of I'd progress provide making clinical the remaining Now, with minutes, like brief to a programs. update couple the on for company on the we're you
We contribute in have the open therapy let's shock clinical in First multiple to line, randomized executing of of that executing Germany. also sites the sites enrollment. amendment now protocol in in earlier those will should faster an refractory with process, process majority that are talk we're allow in of and study and initiation important about patients a
use of our This hemoperfusion with therapy. other but of suggest pump. are its before therapy This maximized initiation replacement real was optimization with earlier benefits and also by continued of trial CTC studies, organ use aligned patients the CytoSorb now is with from commercialization that our results, observations to they require registry like testimonials informed from from develop offering strategy world organ including a approach also of failure treatment support with standalone excellent own renal the that
year to completed the process faster the We drive XXXX. first and anticipate amendment to this in enrollment be in half of
enrollment registry. Now by care We driven the centers. in to projections. is or let's turn adoption our our heart standard that report I'm registry in is attention removal the happy in own part this that the STAR many exceeding to European anti-thrombotic increasing the of believe ATR of as large
conference we're patients and XXXX readouts more since presentation in have an this of interventional We than initial enrolled, the international EuroPCR already Paris have with XXX is large starting cardiology May. data exciting to the going the for year very
the that Surgery to And present largest will We also the have submitted the an course, European European Amsterdam in the accepted Vienna our additional submissions Society analysis in Cardiothoracic take these of meetings. meeting of of in we cardiovascular place next October Cardiology conference world, in should to be August. also Association plan
year talk COSMOS. the about let's Finally, This will of be year COSMOS.
clinical value to benefits allows proposition of data our the the attention the from this We that for quality progress And years high both of from exception in important wealth and also will come. our areas. increase this but the removal focus that will the CytoSorb We platform all applications therapeutic this across registry of multiple and remaining generate resources believe evidence registry. for a with COSMOS CytoSorb enrollment antithrombotic prioritize the
sites with happy of and first We’re recent that countries, few to opening the the sites enrollment the two in the and a few has uptick are and shown Germany slight the months. – happy first first Spain see
results and international last reminder, presented results meeting Society main a now the as Intensive and previously European Care of Medicine CTC publication. have at for discussed final in have been detail registry, the the we submitted Just the year,
please be the for paper on released be to formal lookout shortly. So the
please. slide Next
I time to presented. to little study cardiac has stood listed since the earnings you the was out European spend new like study would about that presented the last at on online the get was more to study analysis surgery Surgery. and on find – patients formally of were of staph published. reference endocarditis really a the the been now the it refer for you The our call, in that that Cardiothoracic multi-center online, now actually we flurry Association bottom During discussed data
patients can most would carries rates risk morbidity multi-center XX%. endocarditis it endocarditis. total aureus patients of cardiac of endocarditis XXX the underwent the staph In while CytoSorb. The mortality CytoSorb, replacement. with confirm treated and those XX that serious are type results the surgery Staphylococcus without valve were aureus is slide. underwent patients of surgery XX It approach summarized those and study, carries of main of highest a this on
given vasopressor with On the surgery instability. throughout and three the treated in And need the the are on left are period were agents the for after the from of drugs hand support. the need who diagram to post-operative to after that such side, on blood maintain hemodynamic early left you bottom try presence see intravenously for These CytoSorb day reduced operation. had patients out pressure right
at However, specifically different looked is mortality that what’s compelling investigators the rates. more three
all, also patients because to compelling save with in not and toxin. absolute large CytoSorb XX.X%, a mortality, that which part to treated significant XX.X% who sepsis control to authors they of of the number related were but represents ability stated turn needed significantly group. treat toxic those would remove of versus was translate believed XX% of life really day hemolysin to The the device they was CytoSorb of staphylococcal that in those X.X%. First X% of the fact XX XX.X% specific only the shock these expired benefits mortality that reduction then and that at cytokines in the in toxins, but to staphylococcal This look versus lower risk a among
they that specifically Anaesthesiology for the in therapy already recently technology perioperative in the very And included Intensive in mentioned Care practice saying leading that undergoing ticagrelor may of issued complications been fact intraoperative we on cardiac it on the absorption Society reduce bleeding. the aortic be these have emergent European patients has probably guidelines, of with and seen surgery our that XXXX you guidelines for first a in statement as adjuvant happy or management guidelines considered time report press recent hemo have Next the CPB. release to is our slide. that an And finally, are rivaroxaban or to highlight severe
Next from this words going a and probably it’s major next. commercialization And more development hear our will up about strategy slide you to few Christian coming inform how please.
timelines and completing patients the we’re we half now milestone in conclusion, summer. with this of and So second visibility STAR-T spring than for this in hitting the trial enrollment more enrolled confident the have the of
proceed will analysis with is for final enrollment complete the interim preserved interim to be We longer rationale will straight fully full executed. There alpha. since no before the could
anticipate top plan line in STAR-D three approximately We STAR study. end hold year’s with have remains registry by remains our the to practice. restart with that will complete of responsibilities the after is after right patient from four care months becoming on last real ahead results the we STAR-T completes now to removal operational STAR-T. standard schedule of world increasingly anti-thrombotic we and
of year And would international across stream our our we of Europe to therapy. presented in and data have a critical new generating high I our our business all positive KOLs that in we and of of fully of be we enthusiasm we’ll both up team business the all areas. anticipate new will continuous and that therapy. and therapeutic enrollment applications. our flow adoption users staffed in very intent interactions continue increasing for from capable care the tailwinds conferences remind adoption also XXXX our the support process the the priority ongoing like you who finally, major positive therapy and about our critical prioritize in Also, medical express based to of with speeding therapeutic We on at in get that with to this COSMOS is constant of feedback areas our believe affairs evidence publication
And So with attention. would thank turn you I like to to for Christian. Christian? your this, it
